Literature DB >> 29348187

The increasing mortality of idiopathic pulmonary fibrosis: fact or fallacy?

Christopher J Ryerson1,2, Martin Kolb3.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29348187     DOI： 10.1183/13993003.02420-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN： 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  12 in total

1.  Effects of different exercise training programs on the functional performance in fibrosing interstitial lung diseases: A randomized trial.

Authors:  Hatem Essam; Nashwa Hassan Abdel Wahab; Gihan Younis; Enas El-Sayed; Hanaa Shafiek
Journal:  PLoS One       Date:  2022-05-26       Impact factor: 3.752

2.  Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study.

Authors:  Franck F Rahaghi; Zeenat Safdar; Anne Whitney Brown; Joao A de Andrade; Kevin R Flaherty; Robert J Kaner; Christopher S King; Maria L Padilla; Imre Noth; Mary Beth Scholand; Adrian Shifren; Steven D Nathan
Journal:  BMC Pulm Med       Date:  2020-07-14       Impact factor: 3.317

Review 3.  HSP90 Inhibition and Modulation of the Proteome: Therapeutical Implications for Idiopathic Pulmonary Fibrosis (IPF).

Authors:  Ruben Manuel Luciano Colunga Biancatelli; Pavel Solopov; Betsy Gregory; John D Catravas
Journal:  Int J Mol Sci       Date:  2020-07-25       Impact factor: 5.923

4.  Impact of interstitial lung disease and simultaneous lung cancer on therapeutic possibilities and survival.

Authors:  Eniko Barczi; Tamas Nagy; Livia Starobinski; Abigel Kolonics-Farkas; Noemi Eszes; Aniko Bohacs; Adam Domonkos Tarnoki; David Laszlo Tarnoki; Veronika Müller
Journal:  Thorac Cancer       Date:  2020-05-13       Impact factor: 3.500

5.  Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis.

Authors:  Nasreen Khalil; Helene Manganas; Christopher J Ryerson; Shane Shapera; Andre M Cantin; Paul Hernandez; Eric E Turcotte; Joseph M Parker; John E Moran; Gary R Albert; Renata Sawtell; Aline Hagerimana; Pierre Laurin; Lyne Gagnon; Frank Cesari; Martin Kolb
Journal:  Eur Respir J       Date:  2019-03-18       Impact factor: 16.671

6.  Mortality and Respiratory-Related Hospitalizations in Idiopathic Pulmonary Fibrosis Not Treated With Antifibrotics.

Authors:  Vincent Cottin; Paolo Spagnolo; Philippe Bonniaud; Maëva Nolin; Faustine Dalon; Klaus-Uwe Kirchgässler; Tripthi V Kamath; Eric Van Ganse; Manon Belhassen
Journal:  Front Med (Lausanne)       Date:  2021-12-24

7.  Fatty acid nitroalkene reversal of established lung fibrosis.

Authors:  Adolf Koudelka; Veronika Cechova; Mauricio Rojas; Nilay Mitash; Anna Bondonese; Claudette St Croix; Mark A Ross; Bruce A Freeman
Journal:  Redox Biol       Date:  2021-12-29       Impact factor: 10.787

8.  Nanoparticle targeting of de novo profibrotic macrophages mitigates lung fibrosis.

Authors:  Abhalaxmi Singh; Sreeparna Chakraborty; Sing Wan Wong; Nicole A Hefner; Andrew Stuart; Abdul S Qadir; Amitabha Mukhopadhyay; Kurt Bachmaier; Jae-Won Shin; Jalees Rehman; Asrar B Malik
Journal:  Proc Natl Acad Sci U S A       Date:  2022-04-04       Impact factor: 12.779

9.  Impact of Lung Biopsy Information on Treatment Strategy of Patients with Interstitial Lung Diseases: The Glass Is Half Full.

Authors:  Daniel-Costin Marinescu; Andrew Churg
Journal:  Ann Am Thorac Soc       Date:  2022-05

10.  Sex-Related Differences in Murine Models of Chemically Induced Pulmonary Fibrosis.

Authors:  Pavel Solopov; Ruben Manuel Luciano Colunga Biancatelli; Christiana Dimitropoulou; John D Catravas
Journal:  Int J Mol Sci       Date:  2021-05-31       Impact factor: 6.208
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.